Renovo Rx Showcases Targeted Oncology Innovation at MedTech Forum
MOUNTAIN VIEW, Calif., November 4, 2025 — RenovoRx, Inc. (NASDAQ: RNXT), a life sciences company pioneering targeted oncology therapies...
Orphan Drug
Advertisement
Gefurulimab Shows Early and Sustained Efficacy in gMG Patients
Cambridge, UK, 30 October 2025 – Alexion, AstraZeneca Rare Disease, today announced positive results from the global Phase III...
AAVantgarde Secures $141 Million Series B to Advance Gene Therapies for Retinal Diseases
LONDON/MILAN, Nov. 3, 2025 — AAVantgarde Bio has raised $141 million in a Series B financing round, co-led by...
Halia Therapeutics’ Ofirnoflast Gains FDA Orphan Drug Status for MDS
LEHI, Utah, Oct. 23, 2025 — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapies targeting the root...
FDA Grants Fast Track to AJ201 for Kennedy’s Disease Therapy
TAIPEI, Taiwan – October 23, 2025 AnnJi Pharmaceutical Co., Ltd. (AJ Pharm) announced that the U.S. Food and Drug...
Advertisements
Oculis Highlights Late-Stage Eye Pipeline at AAO 2025
October 14, 2025 | Zug, Switzerland — Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company advancing therapies for...
Star Therapeutics Raises $125M to Advance Bleeding Disorder Therapy
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2025 — Star Therapeutics announced it has closed an oversubscribed $125 million Series...
FDA Accelerates First-Ever Barth Syndrome Therapy, FORZINITY™
NEEDHAM, Mass., September 19, 2025 – Stealth BioTherapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA)...
Intellia Completes Phase 3 Enrollment for HAE Gene Therapy
September 18, 2025 — Cambridge, Massachusetts Intellia has completed enrollment in the global Phase 3 HAELO trial of lonvoguran...
Health Canada Approves Bylvay for Cholestatic Pruritus in ALGS
OTTAWA, Canada, September 9, 2025 — Health Canada has granted approval to Bylvay™ (odevixibat) for the treatment of cholestatic...
Advertisement
